March 2025 in “Journal of Drugs in Dermatology” This study developed a physician-guided algorithm to manage cutaneous adverse events from hormonal therapy in cancer patients, aiming to reduce treatment interruptions and enhance quality of life.
2 citations
,
October 2021 in “Exploration of targeted anti-tumor therapy” This review describes oncotherapy-induced alopecia in patients receiving hormone therapy for hormone-receptor-positive breast cancer and concludes that topical hormones should not be used due to oncogenic potential.
65 citations
,
November 2019 in “European Journal of Pharmacology” This review discusses the role of anti-androgen therapies in cancer and other diseases and reports no new clinical results, highlighting both old and new generations of anti-androgens.
18 citations
,
August 2019 in “Clinical breast cancer” This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.
9 citations
,
January 2014 in “Annals of Dermatology” In this report, five female patients undergoing hormonal anticancer therapy for breast cancer prevention developed pattern alopecia, which the authors attribute to androgen-estrogen imbalance caused by antiestrogenic drugs.